Area of research
Orthopedics and Sports Medicine · Oncology
Research interest
Research interests include Medicine, Osteoporosis, Internal medicine, Intensive care medicine, Bone mineral, and Denosumab.
X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline
Asia–Pacific consensus for the management of osteoporosis in men
Updated practice guideline for dual-energy X-ray absorptiometry (DXA)
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices
Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk
Proceedings of the 2024 Santa Fe Bone Symposium: Update on the Management of Osteoporosis and Rare Bone Diseases
Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post‐Fracture Treatment, and All‐Cause Mortality
Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases
The clinician’s guide to prevention and treatment of osteoporosis
Is it time to consider population screening for fracture risk in postmenopausal women? A position paper from the International Osteoporosis Foundation Epidemiology/Quality of Life Working Group
Correction to: The clinician’s guide to prevention and treatment of osteoporosis
American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update
Global epidemiology of hip fractures: a study protocol using a common analytical platform among multiple countries
Teriparatide: Label changes and identifying patients for long-term use
American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update
American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis— 2020 Update Executive Summary
Management of Primary Hyperparathyroidism
<i>T</i>-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
Favorable skeletal benefit/risk of long-term denosumab therapy: A virtual-twin analysis of fractures prevented relative to skeletal safety events observed
Racial disparities, FRAX, and the care of patients with osteoporosis
Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial
Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics
Dual-energy X-ray Absorptiometry Monitoring with Trabecular Bone Score: 2019 ISCD Official Position
Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study